Atropine and glycopyrrolate as ECT preanesthesia

Area of Science:

• Anesthesiology
• Pharmacology
• Neurology

Background:

• Preanesthetic medications are crucial for managing patient comfort and physiological stability during electroconvulsive therapy (ECT).
• Atropine and glycopyrrolate are commonly considered anticholinergic agents for preanesthetic use, each with distinct pharmacological profiles.
• Comparing their efficacy and safety in the context of ECT is essential for optimizing patient care.

Purpose of the Study:

• To systematically compare the effects of atropine and glycopyrrolate as preanesthetic agents in patients undergoing electroconvulsive therapy (ECT).
• To evaluate and contrast the incidence of specific adverse events, including cardiac arrhythmias, bradycardia, and gastrointestinal disturbances, between the two agents.

Main Methods:

• A systematic study involving twenty-four patients undergoing ECT.
• Administration of two different dosages for each agent: atropine and glycopyrrolate.
• Monitoring and comparison of preanesthetic effects and post-procedural outcomes.

Main Results:

• Glycopyrrolate was associated with a higher incidence of cardiac arrhythmias, nausea, vomiting, and bradycardia compared to atropine (p = .4).
• A greater number of patients receiving atropine experienced post-ECT confusion, although this effect was clinically minimal.
• Atropine demonstrated a potentially more favorable side effect profile in the context of ECT preanesthesia.

Conclusions:

• Atropine appears to be a preferable preanesthetic agent over glycopyrrolate for patients undergoing electroconvulsive therapy.
• The findings suggest that atropine may offer a better balance of efficacy and reduced adverse events in ECT settings.
• Further research could explore optimal dosing strategies for atropine in ECT preanesthesia.